Gaming and Leisure Properties Inc. Common Stock vs Vertex Pharmaceuticals Incorporated — how do they compare? Gaming and Leisure Properties Inc. Common Stock trades at $38.13 (market cap $11.15B), while Vertex Pharmaceuticals Incorporated trades at $503 (market cap $122.98B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 11× Gaming and Leisure Properties Inc. Common Stock's market cap, and Gaming and Leisure Properties Inc. Common Stock pays a 8.56% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gaming and Leisure Properties Inc. Common Stock for 0 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| GLPI | VRTX | |
|---|---|---|
Market Cap | $11.15B | $122.98B |
Volume | 1,865,490 | 1,155,743 |
Sector | Real Estate | Health |
52-Week High | $49.82 | $557.96 |
52-Week Low | $37.59 | $407.90 |
Typical Hold Time | 0 Days | 120 Days |
Enterprise Value | $19.21B | $117.11B |
Dividend Yield | 8.56% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Vertex Pharmaceuticals (VRTX) trades at $498.50, down 1.68% amid mixed technical signals. The stock shows strong fundamentals with $12B revenue, 35% net margins, and robust cash flow. Recent positive Phase 2b data for kidney drug inaxaplin and cystic fibrosis dominance support growth. Technical indicators show bearish momentum with support at $496 and resistance at $512.
Outlook remains positive with 86% analyst buy ratings and $573.50 price target. Key risks include clinical trial outcomes and competitive pressures. The company's expanding pipeline and profitability provide upside potential, though near-term volatility may persist around key technical levels.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Gaming and Leisure Properties Inc. is a real estate investment trust that acquires, finances, and owns casino and gaming properties, which it leases to gaming operators under triple-net lease arrangements. It was the first publicly traded REIT focused on the gaming real estate sector in North America.
Read more on GLPI →Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →